Sabra Health Care REIT heads into the week with a split signal: short sellers are quietly reducing exposure while Raymond James reinstates coverage with an Underperform rating, putting the Street's caution on record just as the stock slips 10% over the past month to $18.56.
The positioning picture is less alarming than the headline short interest implies. At nearly 12% of the free float, short interest is elevated — but it fell 5% on the week and is down from a local peak near 31 million shares in early June. Borrow costs remain near-trivial at 0.51%, up about 13% on the week but still well within "easy borrow" territory. Availability is comfortable at 285%, meaning roughly three shares are available for every two already borrowed — lenders face no squeeze pressure. Options traders are nudging more defensive: the put/call ratio of 0.28 runs about 1.8 standard deviations above its 20-day average of 0.24, the most protective lean seen since May. It is still far below the 52-week high of 0.62, so the caution is mild rather than panicked. Taken together, positioning looks wary but not crowded.
The analyst picture tells a more pointed story. Raymond James reinstated coverage today with an Underperform rating — a negative turn that arrives against a backdrop of mostly sideways action from the rest of the Street. Wells Fargo maintained Overweight in early June, lifting its target to $23 from $22. Scotiabank and UBS both raised targets in May, keeping Sector Perform and Neutral ratings, respectively. The consensus remains a Hold, with eight analysts in that camp and a mean target around $22 — implying roughly 19% upside from current levels, though the gap between that target and a $18.56 print suggests the Street sees value while remaining unwilling to commit. The EV/EBITDA multiple has drifted down modestly over the past month to 13.4x, and price-to-book has compressed to 1.56x. Bulls point to improving occupancy, favourable senior housing demand, and an above-average RIDEA exposure. Bears — and Raymond James now explicitly — flag higher-than-peer leverage, operator unpredictability, and a stock that was trading near the top of its 10-year valuation range before this month's pullback.
The ORTEX short score of 70.7 is worth watching in context. It has crept up from around 55 six months ago, tracking a dramatic improvement in forward EPS estimates — the 12-month forward EPS year-on-year change reportedly swung from deeply negative in late 2025 to firmly positive today. Yet the short score ranks in the 3rd percentile of the sector, and the dividend score sits in the 96th percentile, suggesting income-focused institutional holders remain a significant stabilising force. BlackRock holds 15.5% of shares, with Principal Global Investors at 9.9% and Vanguard entities collectively above 13%. JP Morgan Asset Management added over 5 million shares in its most recent report — a notably large move for a mid-tier holder. The ownership base skews heavily toward passive and income-oriented mandates, which limits the free-floating supply that short sellers can work with, even with 12% of the float already shorted.
Peer performance through the week reinforces the relative underperformance story. OHI lost only 0.4% on the week. WELL gained 3.3% and VTR rose 1.7%. CTRE dropped 1.8%, roughly in line with SBRA's 1.8% weekly decline — but the broader group moved higher while SBRA did not. With the next earnings event scheduled for August 3, the immediate focus will be whether the Raymond James Underperform call draws further downgrades or whether Wells Fargo's Overweight becomes a more isolated position on the board.
See the live data behind this article on ORTEX.
Open SBRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
